1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 596-599

  Whitlock, Gavin A ^a   Blagg, Julian ^a   Fish, Paul V ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

hERG affinity; Metabolic stability; Monoamine reuptake inhibitor; Noradrenaline; Serotonin

Indexed keywords

1 (2 PHENOXYPHENYL)METHANAMINE DERIVATIVE; POTASSIUM CHANNEL HERG; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; STRUCTURE ACTIVITY RELATION;

AMINES; CELL MEMBRANE PERMEABILITY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MOLECULAR CONFORMATION; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38349102165     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.080     Document Type: Article

References (19)

1. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
2. Fray M.J., Bish G., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4349
3. Fish P.V., Fray M.J., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 17 (2007) 2022
4. Joffe R.T., Marshall A.M., and Lee D.K. J. Clin. Psychiatry 59 (1998) 515
5. Hellerstein D.J., Batchelder S.T., Little S.A.S., Fedak M.J., Kreditor D., and Rosenthal J. J. Clin. Psychiatry 60 (1999) 845
6. Bauer M., Moeller H.-J., and Schneider E. Expert. Opin. Pharmacother. 7 (2006) 421
7. Rowbotham M.C., Goli V., Kunz N.R., and Lei D. Pain 110 (2004) 697
8. Wernicke J.F., Pritchett Y.L., D'Souza D.N., Waninger A., Tran P., Iyengar S., and Raskin J. Neurology 67 (2006) 1411
9. Moore K. Int. J. Gynecol. Obstet. 86 (2004) S53-S62
10. Thor K.B. Int. J. Gynecol. Obstet. 86 (2004) S38-S52
11. Millard R.J., Moore K., Rencken R., Yalcin I., and Bump R.C. BJU Int. 93 (2004) 311
12. Steers W.D., Herschorn S., Kreder K.J., Moore K., Strohbehn K., Yalcin I., and Bump R.C. BJU Int. 100 (2007) 337
13. Kung H.F., Newman S., Choi S.-R., Oya S., Hou C., Zhuang Z.-P., Acton P.D., Ploessl K., Winkler J., and Kung M.-P. J. Med. Chem. 47 (2004) 5258
14. Vercouillie J., Mavel S., Galineau L., Ragusa T., Innis R., Kassiou M., Chalon S., Dolle F., Besnard J.-C., Guilloteau D., and Emond P. Bioorg. Med. Chem. Lett. 16 (2006) 1297
15. 50 values, that is, concentration required to inhibit the specific uptake of radiolabelled substrate into the cells by 50% relative to maximum (vehicle only) over a 10-point dose response range. A minimum of three experiments were made
16. Metabolite identification studies demonstrated that N-demethylation to the secondary amine was the major route of metabolism.
17. Middleton D.S., Andrews M., Glossop P., Gymer G., Jessiman A., Johnson P.S., MacKenny M., Pitcher M.J., Rooker T., Stobie A., Tang K., and Morgan P. Bioorg. Med. Chem. Lett. 16 (2006) 1434
18. Avdeef A., Bendels S., Di L., Faller B., Kansy M., Sugano K., and Yamauchi Y. J. Pharm. Sci. 96 (2007) 2893
19. Zhu C., Jiang L., Chen T.-M., and Hwang K.-K. Eur. J. Med. Chem. 37 (2002) 399